RESUMO
We tested the influence of recombinant human interleukin (rhIL)-l3 and rhIL-4 on clonal growth of human breast cancer cell lines. rhIL-13 and rhIL-4 inhibited clonal growth of three of nine lines to approximately 50% of controls (ED50, 0.5 ng/ml). rhIl-13 reduced [3H]thymidine incorporation in all three cell lines: two showing a minor (84% and 83% of controls) and one showing a major response (25% of control). Both cytokines markedly reduced serum-induced G(0/1) exit (approximately 25% versus 60%). 125I-labeled interleukin (IL) 13 binding assays revealed high-affinity binding sites for IL-13 on two of the three responding cell lines (KD approximately 60 pM). (Y124D)IL-4 effectively antagonized all effects of rhIl-13 and rhIL-4, arguing for shared receptor components between them. However, neither rhIl-4 nor (Y124D) IL-4 could displace 125I-labeled IL-13 from binding, although unlabeled rhIL-13 effectively did so. Using reverse transcription-PCR, we studied the expression of the common gamma chain (gammac) in responding cell lines, putatively being shared between IL-4 receptor and IL-13 receptor; none of the three cell lines express gammac. In conclusion, we demonstrate antiproliferative effects of IL-4 and IL-13 on carcinoma cells which express IL-13 binding sites without participation of gammac.
Assuntos
Antineoplásicos/farmacologia , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Interleucina-13/farmacologia , Animais , Antígenos CD/metabolismo , Antineoplásicos/metabolismo , Sequência de Bases , Sítios de Ligação , Células CHO , Ciclo Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Cricetinae , DNA de Neoplasias/biossíntese , Humanos , Interleucina-13/metabolismo , Subunidade alfa1 de Receptor de Interleucina-13 , Interleucina-4/farmacologia , Radioisótopos do Iodo , Dados de Sequência Molecular , Receptores de Interleucina/metabolismo , Receptores de Interleucina-13 , Receptores de Interleucina-4 , Proteínas Recombinantes/farmacologia , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/fisiologia , Células Tumorais CultivadasRESUMO
In a group of 44 healthy probands, the change in bile-duct size after ingestion of a gastric stimulant in the early stage of the regulation was examined. From an empty diameter of 5.62 mm, a statistically significant reduction to 4.00 mm was found after 5 min, followed by a further slight reduction to 3.86 mm after 10 min and to 3.57 mm after 20 min. The physiological basis is the influence of cholecystokinin on the ductus hepatocholedochus and the sphincter of Oddi. This eliminates the long examination and observation intervals typical of radiological diagnostics and justifies early functional sonographic investigation of the bile duct during abdominal sonography, which does not involve an additional time investment.
